Nick Medjeral-Thomas (@NickRhysMT) profile picture

KRUK/IC clinical research fellow, nephrology and GIM dr, proud dad, spectacular husband. None of this is clinical advice. Views often inspired by clever people

Joined February 2011
Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)Photo by Nick Medjeral-Thomas (@NickRhysMT)
This describes our experience managing #haemodialysis patients with #COVIDー19 @ImperialNHS community dialysis unit incl risk factors for deterioration and (zero) staff infections kireports.org/article/S2468-…
1
6
Nick Medjeral-Thomas retweeted
Pleased to see our paper available preprint. Huge collaborative effort from clinicians, scientists, dialysis nurses and patients @imperialcollege @ImperialImmuno @ImperialNHS @mkwillicombe @Maria_Prend @stephenmcadoo @NickRhysMT
2
3
7
Proud to be part of this huge effort from scientists and clinicians to detail longitudinal proteomic profiles of end-stage kidney disease patients with #COVID19 #medRxiv @ImperialImmuno @ImperialNHS @clclarke227 @jack_gisby medrxiv viewer disq.us/t/3splu24
1
2
Nick Medjeral-Thomas retweeted
What to do with the relapses. Rechallenge with Tac? #nephjc
2
1
1
1
Nick Medjeral-Thomas retweeted
Patients themselves often ask if there's an alternative an alternative to steroids. #NephJC
#NephJC. Nick Medjeral-Thomas. MinTac author. No other COI
1
1
1
9
MinTac Trial: Tacrolimus monotherapy can be an effective alternative treatment for patients wishing to avoid steroid therapy for minimal change disease ca. 2020 from @CJASN @NickRhysMT @megan_griffith1 @IgAN_JBarratt @neilturn @Profcpusey #Nephpearls 👉🏼 cjasn.asnjournals.org/conten… – at Riverside, IL
15
20
Tacrolimus works as well as steroids for adult minimal change disease, from @NickRhysMT & @megan_griffith1 Day 1 #KidneyWk highlights
1
9
2
20
Glomerular complement deposition, in particular FHR5. Next 😉
I’m convinced! From Famine to Feast - clinical trials in #IgAN from Dana Rizk at @ASNKidney #KidneyWk. But how do we select and stratify our patient for all these competing studies? @NickRhysMT @IgAN_JBarratt
5
Nick Medjeral-Thomas retweeted
#KidneyWk #MinimalChange groundbreaking study showing it is possible to avoid steroids in patients with minimal change
Thanks to all collaborators on the Mintac trial. Results will empower patients with minimal change disease to make informed choices about their treatment. @NickRhysMT @1mariecondon @BhriguSood @IgAN_JBarratt @neilturn @k1dny @kidneydoc101 @jeremyblevy @Profcpusey
3
8
Nick Medjeral-Thomas retweeted
Grilling them? Ha, nah, more like praising them. Important work from @megan_griffith1 and @NickRhysMT providing an efficacious alternative to high dose steroids for minimal change podocytopathy. @LGlomcon #KidneyWk – at Washington, DC
At #KidneyWk @VelezNephHepato grilling @NickRhysMT & Megan Griffith But tacrolimus monotherapy seems similar to prednisone in MCD in this trial #KidneyWk
2
5
Nick Medjeral-Thomas retweeted
Thanks to all collaborators on the Mintac trial. Results will empower patients with minimal change disease to make informed choices about their treatment. @NickRhysMT @1mariecondon @BhriguSood @IgAN_JBarratt @neilturn @k1dny @kidneydoc101 @jeremyblevy @Profcpusey
4
27
3
60
📖 For this weekend don't miss our @KIReports #FridaySelection: Glomerular Complement Factor H–Related Protein 5 Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. 👉🏼 doi.org/10.1016/j.ekir.2019.… @NickRhysMT @ImperialMed #GraphicalAbstract #ThisIsISN
5
5
Outstanding key note C1q story from Marina Botto #emchd2019 Paradigm-shifting data made accessible with explanations like, of course C1q has functions independent of Ig because it phylogenetically predates Immunoglobulin science.sciencemag.org/conte…
2
6
Joshua Thurman #emchd2019 is leukocyturia an overlooked market of eculizumab treatment response cjasn.asnjournals.org/conten…
1
2
5
Joshua Thurman reminds us that confound factors, esp non-specific loss of GFR, must be quantified before applying potential complement biomarkers to clinical practice (fig from Jalal et al, JAHA 2018) #emchd2019
2
2
Thrilled to attend this complement-fest. #C3G satellite meeting today promises novel insights and productive discussion (and my lightning C3G immunostaining presentation!) watch this #EMCHD2019 space complephiles!
2
1
8